Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here for more information

CiteULike is a free service for managing and discovering scholarly references - click here to get started.

Sign In to gain access to subscriptions and/or personal tools.
Journal of Child Neurology
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Pollack, I. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pollack, I. F.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Diagnostic and Therapeutic Stratification of Childhood Brain Tumors: Implications for Translational Research

Ian F. Pollack, MD, FACS, FAAP

Department of Neurosurgery, Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, ian.pollack{at}chp.edu

Recent advances in the categorization of childhood brain tumors have improved risk-based treatment planning. In several instances, new therapeutic strategies that incorporate these advances have resulted in meaningful improvements in progression-free and overall survival. Current studies are directed at further refining therapy based on clinical, biological, and molecular data; testing the effectiveness of a number of novel therapeutic strategies for high-risk tumors; and examining approaches to reduce sequelae of treatment among more favorable-risk tumor subsets. Because multiple tumor subtypes are individually relatively uncommon, most such studies are being conducted by large co-operative groups, such as the Children's Oncology Group, or by smaller brain tumor-focused consortia, such as the Pediatric Brain Tumor Consortium.

Key Words: brain tumor • pediatric • molecular marker • prognostic factor

References

  • Pollack IF Brain tumors in children. N Engl J Med. 1994;331:1500-1507.[Free Full Text]
  • Jennings MT, Sposto R., Boyett JM, et al. Preradiation chemotherapy in primary high-risk brainstem tumors: phase II study CCG-9941 of the Children's Cancer Group. J Clin Oncol. 2002;20:3431-3437.[Abstract/Free Full Text]
  • Radcliffe J., Packer RJ, Atkins TE, et al. Three- and four-year cognitive outcome in children with noncortical brain tumors treated with whole-brain radiotherapy. Ann Neurol. 1992;32: 551-554.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Evans AE, Jenkin RD, Sposto R., et al. The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg. 1990;72:572-582.[Web of Science][Medline] [Order article via Infotrieve]
  • Tait DM, Thornton-Jones H., Bloom HJG, Lemerle J., Morris-Jones P. Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). Eur J Cancer. 1990;26:464-469.[Web of Science][Medline] [Order article via Infotrieve]
  • Zeltzer PM, Boyett JM, Finlay JL, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol. 1999;17:832-845.[Abstract/Free Full Text]
  • Packer R., Gajjar A., Vezina G., et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy regimens for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006;24:4202-4208.[Abstract/Free Full Text]
  • Pizer BL, Weston CL, Robinson KJ, et al. Analysis of patients with supratentorial primitive neuro-ectodermal tumours entered into the SIOP/UKCCSG PNET 3 study. Eur J Cancer. 2006;42:1120-1128.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Thomas RM, Deutsch M., Kepner JL, et al. Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol. 2000;18: 3004-3011.[Abstract/Free Full Text]
  • Gajjar A., Hernan R., Kocak M., et al. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol. 2004;22:984-993.[Abstract/Free Full Text]
  • Gilbertson RJ, Perry RH, Kelly PJ, Pearson AD, Lunec J. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res. 1997;57:3272-3280.[Abstract/Free Full Text]
  • Grotzter MA, Janss AJ, Fung K., et al. TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J Clin Oncol. 2000;18:1027-1035.[Abstract/Free Full Text]
  • MacDonald TJ, Brown KM, LaFleur B., et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet. 2001;29:143-152.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pomeroy S., Goumnerova LC, Tamayo P., et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. 2002;415:436-442.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Northcott P., Nakahara Y., Peacock J., et al. Identification of known and novel recurrent amplified oncogenes in pediatric medulloblastoma [abstract]. Neuro Oncol. 2007;9:554.
  • Segal RA, Goumnerova LC, Kwon YK, Stiles CD, Pomeroy SL Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. Proc Natl Acad Sci U S A. 1994;91:12867-12871.[Abstract/Free Full Text]
  • Miralbell R., Fitzgerald TJ, Laurie F., et al. Radiotherapy in pediatric medulloblastoma: quality assessment of Pediatric Oncology Group Trial 9031. Int J Radiat Oncol Biol Phys. 2006;64:1325-1330.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Taylor RE, Bailey CC, Robinson KJ, et al. Outcome for patients with metastatic (M2-3) medulloblastoma treated with SIOP/ UKCCSG PNET-3 chemotherapy. Eur J Cancer. 2005;41: 727-734.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Jakacki R., Burger P., Zhou T., et al. Outcome for metastatic (M+) medulloblastoma (MB) treated with carboplatin during craniospinal radiotherapy (CSRT) followed by cyclophosphamide (CPM) and vincristine (VCR). J Clin Oncol. 2007;25:75S.
  • Berman DM, Karhadkar SS, Hallahan AR, et al. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science. 2002;297:1559-1561.[Abstract/Free Full Text]
  • Hallahan AR, Pritchard JI, Hansen S., et al. The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res. 2004;64:7794-7800.[Abstract/Free Full Text]
  • Finlay JL, Boyett JM, Yates AJ, et al. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. J Clin Oncol. 1995;13:112-123.[Abstract/Free Full Text]
  • MacDonald TJ, Arenson EB, Ater J., et al. Phase II study of high-dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytoma: final analysis of Children's Cancer Group Study 9933. Cancer. 2005;104:2862-2871.[Medline] [Order article via Infotrieve]
  • Sposto R., Ertel IJ, Jenkin RD, et al. The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group. J Neurooncol. 1989;7:165-177.[CrossRef][Medline] [Order article via Infotrieve]
  • Wisoff JH, Boyett JM, Berger MS, et al. Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group trial no. CCG-945. J Neurosurg. 1998;89:52-59.[Web of Science][Medline] [Order article via Infotrieve]
  • Pollack IF, Finkelstein SD, Woods J., et al. Expression of p53 and prognosis in malignant gliomas in children. N Engl J Med. 2002;346:420-427.[Abstract/Free Full Text]
  • Pollack IF, Hamilton RL, Burnham J., et al. The impact of proliferation index on outcome in childhood malignant gliomas: results in a multi-institutional cohort. Neurosurgery. 2002;50: 1238-1244.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pollack IF, Hamilton RL, Sobol RW, et al. MGMT expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 cohort. J Clin Oncol. 2006;24: 3431-3437.[Abstract/Free Full Text]
  • Stupp R., Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med. 2005;352:987-996.[Abstract/Free Full Text]
  • Jakacki R., Yates A., Zhou T., et al. Temozolomide as part of combination chemotherapy for pediatric brain tumors: the Children's Oncology Group experience [abstract]. Neuro Oncol. 2007;9:188.
  • Faury D., Nantel A., Dunn SE, et al. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol. 2007;25: 1196-1208.[Abstract/Free Full Text]
  • Khatua S., Peterson KM, Brown KM, et al. Overexpression of the EGFR/FKBP12/HIF-2alpha pathway identified in childhood astrocytomas by angiogenesis gene profiling. Cancer Res. 2003;63:1865-1870.[Abstract/Free Full Text]
  • Wong KK, Tsang YTM, Chang YM, et al. Genome-wide allelic imbalance analysis of pediatric gliomas by single nucleotide polymorphic allele array. Cancer Res. 2006;66:11172-11178.[Abstract/Free Full Text]
  • Fouladi M., Nicholson HS, Zhou T., et al. A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/ primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study. Cancer. 2007;110:2535-2541.[Medline] [Order article via Infotrieve]
  • Kieran MW, Packer RJ, Onar A., et al. Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. J Clin Oncol. 2007;25:3137-3143.[Abstract/Free Full Text]
  • Pollack IF, Jakacki RI, Blaney SM, et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol. 2007;9:145-160.[Abstract/Free Full Text]
  • Epstein F., McCleary EL Intrinsic brain-stem tumors of childhood: surgical indications. J Neurosurg. 1986;64:11-15.[Web of Science][Medline] [Order article via Infotrieve]
  • Pollack IF, Hoffman HJ, Humphreys RP, Becker L. The long-term outcome after surgical treatment of dorsally exophytic brain-stem gliomas. J Neurosurg. 1993;78:859-863.[Web of Science][Medline] [Order article via Infotrieve]
  • Dunkel IJ, Garvin JH, Goldman S., et al. High dose chemotherapy with autologous bone marrow rescue for children with diffuse pontine brain stem tumors. J Neurooncol. 1998;37: 67-73.[CrossRef][Medline] [Order article via Infotrieve]
  • Jenkin RD, Boesel C., Ertel I., et al. Brain-stem tumors in childhood: a prospective randomized trial of irradiation with and without adjuvant CCNU, VCR, and prednisone. A report of the Childrens Cancer Study Group. J Neurosurg. 1987;66:227-233.[Web of Science][Medline] [Order article via Infotrieve]
  • Kretschmar CS, Tarbell NJ, Barnes PD, Krischer JP, Burger PC, Kun L. Pre-irradiation chemotherapy and hyperfractionated radiation therapy 66Gy for children with brain stem tumors. Cancer. 1993;72:1404-1413.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Needle MN, Mehta M., Krailo M., et al. Phase I study of topotecan as a radiosensitizer prior to daily involved field irradiation in children with intrinsic pontine glioma. A Children's Cancer Group study [abstract]. Proc Am Soc Clin Oncol. 1999;18:558a.
  • Sanghavi SN, Needle MN, Krailo MD, et al. A phase I study of topotecan as a radiosensitizer for brainstem glioma of childhood: first report of CCG-0952. Neuro Oncol. 2003;1:8-13.
  • Mehta M., Forouzannia A., Ames M., et al. Phase I study of motexafin-gadolinium (M-Gd) as a radiosensitizer for pediatric intrinsic pontine glioma (BSG): A Children's Oncology Group Study. Proc Am Soc Clin Oncol. 2001;20:243a.
  • Gilbertson RJ, Hill A., Hernan R., et al. ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma. Clin Cancer Res. 2003;9:3620-3624.[Abstract/Free Full Text]
  • Packer RJ, Ater J., Allen J., et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg. 1997;56:747-754.
  • Prados MD, Edwards MS, Rabbitt J., Lamborn K., Davis RL, Levin VA Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen. J Neurooncol. 1997;32:235-241.[Medline] [Order article via Infotrieve]
  • Ater J., Holmes E., Zhou T., et al. Treatment of young children with progressive or symptomatic low-grade glioma with chemotherapy: preliminary report from the Children's Oncology Group (COG) Phase 3 protocol A9952. Neuro Oncol. 2006;8:465.
  • Bouffet E., Goldman S., Jakacki R., et al. Pilot study of vinblastine in patients with recurrent and refractory low grade glioma. Neuro Oncol. 2004;6:450.
  • Wong KK, Chang YM, Tsang YTM, et al. Expression analysis of juvenile pilocytic astrocytomas by oligonucleotide micro-array reveals two potential subgroups. Cancer Res. 2005;65: 76-84.[Abstract/Free Full Text]
  • Duffner PK, Horowitz ME, Krischer JP, et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. New Engl J Med. 1993;328:1725-1731.[Abstract/Free Full Text]
  • Geyer JR, Sposto R., Jennings M., et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. J Clin Oncol. 2005;23:7621-7631.[Abstract/Free Full Text]
  • Rutkowski S., Bode U., Deinlein F., et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. New Engl J Med. 2005;352:978-986.[Abstract/Free Full Text]
  • Biegel JA, Zhou J.-Y, Rorke LB, et al. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res. 1999;59:74-79.[Abstract/Free Full Text]
  • Judkins AR, Burger PC, Hamilton RL, et al. INI1 protein expression distinguishes atypical teratoid/rhabdoid tumor from choroid plexus carcinoma. J Neuropathol Exp Neurol. 2005;64:391-397.[Web of Science][Medline] [Order article via Infotrieve]
  • Hilden JM, Meerbaum S., Burger P., et al. Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry. J Clin Oncol. 2004;22: 2877-2884.[Abstract/Free Full Text]
  • Tekautz TM, Fuller CE, Blaney S., et al. Atypical teratoid/ rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J Clin Oncol. 2005;23:1491-1499.[Abstract/Free Full Text]

Journal of Child Neurology, Vol. 23, No. 10, 1179-1185 (2008)
DOI: 10.1177/0883073808321770
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 J Child NeurolHome page
R. A. Brumback
Child Neurologists Should Be Interested In Brain Tumors!
J Child Neurol, November 1, 2009; 24(11): 1338 - 1340.
[PDF]

This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Pollack, I. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pollack, I. F.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?